Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Characterization and visualization of murine coagulation factor VIII-producing cells in vivo


Coagulation factors are produced from hepatocytes, whereas production of coagulation factor VIII (FVIII) from primary tissues and cell species is still controversial. Here, we tried to characterize primary FVIII-producing organ and cell species using genetically engineered mice, in which enhanced green fluorescent protein (EGFP) was expressed instead of the F8 gene. EGFP-positive FVIII-producing cells existed only in thin sinusoidal layer of the liver and characterized as CD31high, CD146high, and lymphatic vascular endothelial hyaluronan receptor 1 (Lyve1)+. EGFP-positive cells can be clearly distinguished from lymphatic endothelial cells in the expression profile of the podoplanin and C-type lectin-like receptor-2 (CLEC-2)+. In embryogenesis, EGFP-positive cells began to emerge at E14.5 and subsequently increased according to liver maturation. Furthermore, plasma FVIII could be abolished by crossing F8 conditional deficient mice with Lyve1-Cre mice. In conclusion, in mice, FVIII is only produced from endothelial cells exhibiting CD31high, CD146high, Lyve1+, CLEC-2+, and podoplanin in liver sinusoidal endothelial cells.


Blood coagulation factor VIII (FVIII), a procofactor in the process of blood coagulation, is catalyzed into an activated form (FVIIIa) at the site of vascular injury. FVIIIa binds to coagulation factor IX on the activated platelet surface and facilitates factor X activation in the intrinsic coagulation pathway1. Hemophilia A is a common congenital hemorrhagic disorder that is caused by FVIII deficiency and mainly affects men2. Because liver transplantation could increase FVIII levels in patients with hemophilia A, the liver is considered the source of plasma FVIII3,4. However, plasma FVIII levels are not affected by liver dysfunction5, suggesting an exceptional mode of protein production from the liver. It was reported that FVIII could be produced from hepatocytes and endothelial cells, but not Kupffer cells6. FVIII production is elevated in patients with cirrhosis, which is associated with increased overgrowth of FVIII-producing endothelial cells5. Moreover, studies on organ transplantation reported several other origins of circulating FVIII. Plasma FVIII levels were reportedly increased by transplantation of the lymph nodes, spleen cells, bone marrow, and lung in several animal models and in patients with hemophilia A3,4,7,8,9,10,11, suggesting the existence of FVIII production from extrahepatic organs.

Previous elegant studies using genetically engineered mice reported that the source of FVIII is restricted to endothelial cells because the conditional deletion of mouse genes encoding FVIII and mannose-specific lectin (F8 and Lman1, respectively) in endothelial cells specifically reduced plasma FVIII levels12,13. F8 messenger RNA (mRNA) expression has been detected in several organs14, and FVIII synthesis was observed from endothelial cells isolated from anatomically diverse organs such as liver sinusoidal endothelial cells (LSECs), glomerular endothelial cells, blood outgrowth endothelial cells, and lung microvascular endothelial cells15,16,17,18. FVIII and von Willebrand factor (VWF) proteins were also detected in Weibel–Palade bodies within glomerular microvascular endothelial cells and umbilical vein endothelial cells19. Furthermore, lymphatic endothelial cells were identified as a major cellular source of FVIII in extrahepatic tissues20. These data suggest that various types of endothelial cells from diverse organs are capable of expressing FVIII. However, the actual organs and the cellular characteristics of endothelial cells producing FVIII protein in vivo remain unclear. This study aimed to identify the organs and cells responsible for FVIII production using genetically engineered mice.


Generation of FVIII knock-in mice

We first generated F8flox knock-in mice in which Cre induction led to the elimination of F8 with EGFP expression (Fig. 1a). We further generated F8Δ knock-in (F8Δ-KI) mice with the systemic deletion of F8 by mating F8flox knock-in mice with CAG-Cre mice (Fig. 1a–c) to identify the cells and organs responsible for the production of FVIII protein in vivo. The plasma FVIII:C level in F8Δ-KI mice was confirmed to be < 1%. Because the expression of EGFP in F8Δ-KI mice is regulated by the F8 gene promoter, we used them to identify FVIII-producing cells by EGFP tracking in further experiments.

Figure 1
figure 1

F8 targeting strategy in F8 knock-in mice. (a) Schematic of F8 targeting construct. Diagrams show wild-type allele, targeting vector, targeting allele, floxed allele (F8flox knock-in), and deleted allele (F8Δ knock-in). The targeting vector was constructed by flanking the F8 exons 16–28 cDNA-SV40 polyA and PGK-Neo cassette with loxP sites, followed by linking 2A-EGFP cDNA-SV40 polyA. White boxes, F8 exon 16; dark gray boxes, F8 cDNA including exons 16–28 (stop codon); light gray boxes, 2A-EGFP cDNA; black boxes, SV40 poly A; white arrow, PGK-Neo cassette; black triangles, loxP sites; white triangles, FRT sites; black arrow, DTA. Restriction enzyme sites: Ap, ApaLI; S, SphI; A, ApaI. (b) Southern blotting of targeted embryonic stem cells. Genomic DNA was digested with ApaL I or Sph I, and probed with the 5′ or 3′ probe. Locations of probes are indicated in (a). (c) Confirmation of deletion of F8 cDNA (exons 16–28) in F8Δ knock-in mice. PCR was performed using the indicated F and R primers in (a).

Identification of FVIII-producing cells

We attempted to identify EGFP-positive organs responsible for FVIII production in F8Δ-KI mice by flow cytometry. We focused on CD31-positive endothelial cells in organs because endothelial cells are reported to be a major source of FVIII production12,13. CD31-expressing liver endothelial cells were the only cell population to express EGFP, and no EGFP-positive endothelial cells were detected in the lung, kidney, spleen, intestines, lymph nodes, or bone marrow (Fig. 2a). We further examined the characteristics of EGFP-positive endothelial cells in the liver. Liver endothelial cells were separated into three populations according to their CD31 and CD146 expression profile (Fig. 2b). EGFP expression in F8Δ-KI mice was mainly observed in the CD31highCD146high population, but expression levels of 0.03% and 4.84% were observed in the CD31CD146 population and CD31midCD146mid population, respectively (Fig. 2c).

Figure 2
figure 2

The characterization of EGFP-positive cells in F8Δ knock-in mice. (a) Cells were isolated from the indicated organs in adult wild-type C57BL/6J male mice (WT) and F8Δ knock-in (F8Δ-KI) mice. EGFP and CD31 expressions in the cells were determined by flow cytometry. Plots represent the expression levels of EGFP (horizontal) and CD31 (vertical) after the exclusion of dead cells. Boxes in the liver plots indicate the EGFP-positive population in WT and F8Δ-KI mice. (b) After the exclusion of dead cells and CD45+ cells, liver cells were fractioned into three populations according to the expression levels of CD31 (horizontal) and CD146 (vertical): CD31CD146, CD31midCD146mid, and CD31highCD146high. (c) Based on the three populations in (b), EGFP expression in WT and F8Δ-KI mice was analyzed by histograms. Pink-filled and green-filled histograms indicate WT and F8Δ-KI mice, respectively. (d) Plots represent the expression levels of EGFP (horizontal) and Lyve1 (vertical) in CD31highCD146high liver cells obtained from WT and F8Δ-KI mice. (e) Based on the CD31highCD146high population in (b), podoplanin and CLEC-2 expressions were analyzed in WT and F8Δ-KI mice. The upper plots represent the expression levels of podoplanin (horizontal) and Lyve1 (vertical). The lower plots represent the expression levels of CLEC-2 (horizontal) and Lyve1 (vertical). Upper and lower histograms represent EGFP expression in podoplaninLyve1+ and CLEC-2+Lyve1+ populations, respectively. (ae) The numbers in gated areas indicate the percentage of cells (n = 3).

Lymphatic endothelial cells have previously been reported to be FVIII-producing cells20, and many of their cellular characteristics are common to sinusoidal endothelial cells. The EGFP-positive cells in CD31highCD146high population also expressed Lyve1, a marker for sinusoidal endothelial cells and lymphatic endothelial cells (Fig. 2d). Low levels of Lyve1 expression were also observed in the CD31midCD146mid population with low EGFP expression (Supplementary Fig. S1a). We focused on the expression of podoplanin as a marker for lymphatic endothelial cells to identify the different characteristics between FVIII-producing cells and lymphatic endothelial cells21. Although mAb was useful to detect podoplanin in lung cells (Supplementary Fig. S1b), podoplanin was not expressed in the CD31highCD146highLyve1+ population of the liver, and EGFP-positive cells were detected in the podoplaninLyve1+ population (Fig. 2e). LSECs reportedly express several members of CLEC members22,23,24. EGFP-positive cells in the CD31highCD146highLyve1+ population expressed CLEC-2, a physiological receptor for podoplanin, abundantly expressed on platelets25 (Fig. 2e). These data suggest that FVIII-producing sinusoidal endothelial cell in the liver can be clearly distinguished from lymphatic endothelial cells in the expression profile of podoplanin and CLEC-2.

Localization of FVIII-producing cells

We employed immunohistochemistry for EGFP expression to identify the histological localization of FVIII-producing cells. Immunohistochemical analysis did not detect EGFP expression in liver parenchymal cells (hepatocytes) or around the central vein (Supplementary Fig. S2). Intravital microscopy clearly identified EGFP expression in the liver of F8Δ-KI mice, revealing that EGFP-positive cells were localized to liver endothelial cells constructing thin sinusoids (Fig. 3a, Supplementary Movies 1 and 2).

Figure 3
figure 3

Histological localization of EGFP-positive cells in F8Δ knock-in mice. (a) Intravital imaging in the liver of adult WT and F8Δ-KI male mice was observed by intravital confocal microscopy. Red, blood flow; blue, Hoechst-stained nuclei; white (upper) and green (lower), EGFP. Yellow lines in the top panel indicate thick sinusoidal vasculature. (be) Liver sections obtained from adult F8Δ-KI mice were subjected to immunofluorescence staining for EGFP and CD146 (b), EGFP and Lyve1 (c), EGFP and CLEC-2. (d), and EGFP and VWF. (e) Nuclear localization was simultaneously examined by DAPI staining. Confocal microscopy was used to observe the localization of each antigen, nucleus, and their merged image. The magnifications of the boxed areas in the merged image are shown in the right panel. Scale bars: 75 μm in merged images and 25 μm in magnification of the merged images; *central vein (n = 3).

We stained liver sections with antibodies against endothelial markers, such as CD146, Lyve1, CLEC-2, and VWF (Fig. 3b–e and Supplementary Fig. S3), to further determine the profile of EGFP-positive cells in the liver. CD146-positive endothelial cells were found to be present not only in the sinusoid but also in the central veins (Fig. 3b). Lyve1 and CLEC-2 were only expressed in sinusoidal endothelial cells, whereas the dominant expression of VWF was observed in the central veins (Fig. 3c–e). Taken together, it was observed that EGFP-positive cells localized in the sinusoids and coexpressed CD146, Lyve1, CLEC-2, and VWF.

FVIII-producing cells during development

We next investigated EGFP expression in the liver during the embryonic development of F8Δ-KI mice (Fig. 4a). No EGFP expression was detected in the whole fetus at embryonic day (E)10.5. Of note, EGFP expression in CD31highCD146highLyve1+CLEC-2+ liver endothelial cells surged from 5% at E12.5 to 80% at E14.5. Furthermore, its expression reached more than 90% at birth (Fig. 4a). These results suggest that FVIII in CD31highCD146highLyve1+CLEC-2+ liver endothelial cells expressed in the later phase of embryonic development.

Figure 4
figure 4

Microarray analysis of Lyve1-positive cells in liver during embryonic development. (a) Liver cells were obtained from fetal (E12.5, E14.5, and E16.5), newborn (P0), and adult WT and F8Δ-KI mice. After the exclusion of dead cells and CD45+ cells, EGFP expression was detected in CD31highCD146highLyve1+CLEC-2+ population. Pink-filled and green-filled histograms indicate WT and F8Δ-KI mice, respectively. The numbers in gated areas indicate the percentage of cells (n = 3). (b) Lyve1-positive cells were isolated as CD31highCD146highLyve1+ cells from the liver of C57BL/6J fetal mice (E12.5 and E17.5) (n = 3). Scatter plot of differentially expressed genes in E12.5 Lyve1+ cells and E17.5 Lyve1+ cells. Red and green dots indicate upregulated and downregulated genes with a greater than twofold change, respectively. (c) Percentage of upregulated and downregulated genes with a greater than twofold change. (d) Heatmap of differentially expressed genes related to coagulation factors and endothelial cell markers between E12.5 Lyve1+ cells and E17.5 Lyve1+ cells. Blue and red colors represent low and high expression levels, respectively.

We further examined mRNA expression profiles in Lyve1-positive cells during embryonic development. We isolated CD31highCD146highLyve1+ cells from the liver obtained from E12.5 and E17.5 mouse embryos and compared mRNA expressions by microarray analysis (Supplementary Fig. S4a and Fig. 4b). Of 45,037 probes examined, 8.0% and 7.4% of the genes were found to be significantly decreased or increased more than twofold, respectively (Fig. 4c). We analyzed the expression of coagulation factors and endothelial markers. We confirmed the decrease in CD34 expression and significant increase in Fcgr2b and F8 (Fig. 4d). The genes that were upregulated at E17.5 also included Mcam (CD146) and Lyve1, which were used as cell surface markers for cell sorting. The expressions of other coagulation factors and Vwf were not changed. We also analyzed Clec family members and found dominant expression of Clec2d, Clec14a, Clec1b, and Clec4g (Supplementary Fig. S4b). The upregulated genes such as Clec1b, Clec4g, and Stab2 were also specifically expressed in CD31highCD146highLyve1+ liver endothelial cells of adult mice (Supplementary Fig. S5).

Conditional deletion of F8 in Lyve1-positive endothelial cells

Previous reports suggested mating with Tie2-Cre mice, but not Alb-Cre mice, suppressed FVIII:C expression in F8 conditional deficient mice12,13. We crossed F8 conditional deficient mice with Lyve1-Cre mice to further confirm the importance of sinusoidal endothelial cells for FVIII production. Because Lyve1 is expressed in sinusoidal endothelial cells but not vascular endothelial cells26, Lyve1 promoter enables to more specifically express Cre in sinusoidal endothelial cells than Tie2 promoter. We employed F8fl/fl conditional deficient mice (F8tm1Rmnt/J) possessing 2 loxP sites flanking exons 17–1813. Male offspring of crosses between female F8fl/fl conditional deficient mice and male Lyve1-Cre mice showed a marked decrease in FVIII:C by Cre expression compared with male littermates without Cre expression (Fig. 5). These data clearly support our idea that FVIII was produced predominantly from LSECs.

Figure 5
figure 5

Decrease in plasma FVIII activity by the conditional deletion of F8. Plasma levels of FVIII activity (FVIII:C) were measured by one-stage clotting assay in the conditional knockout F8 male mice obtained by crossing F8 fl/fl mice with Alb-Cre, CAG-Cre, Tie2-Cre, or Lyve1-Cre mice. Dots represent plasma FVIII:C levels in each mouse. Bars are means ± SEM (n = 4–8). ***P < 0.0001 (2-tailed Student’s t-test).


Details of the exact organ and endothelial cell types involved in FVIII synthesis have been controversial for decades3,4,7,8,9,15,16,17,18. To resolve this issue, we generated F8flox knock-in mice in which Cre induction led to the elimination of F8 and expression of EGFP to aid the identification of organs and cells responsible for FVIII production. After the systemic induction of Cre, we could clearly identify FVIII-producing cells as EGFP-positive cells in mouse.

We found that the liver was the only organ to produce FVIII, and sinusoidal endothelial cells exhibiting CD31high, CD146high, Lyve1+, and CLEC-2+ were responsible for FVIII production. This endothelial fraction was not observed in other organs, such as the lung, kidney, spleen, intestines, lymph nodes, and bone marrow. Although previous observation revealed that lymphatic endothelial cells were the major source of extrahepatic FVIII production20, EGFP-positive cells could not be detected in lymph nodes and spleen in this study. Our findings are consistent with the fact that the FVIII:C of patients with hemophilia A reaches a normal range soon after liver transplantation3,4. Sinusoidal endothelial cells and lymphatic endothelial cells substantially share similar cellular and phenotypic characteristics, for example, minimal basement membranes and expression profile of Lyve1+, VSP-1+, and Reelin+ and CD3427. In addition, some members of C-type lectin receptor family such as CLEC-4G and CLEC-4M are expressed in both cells23,24. In contrast, the FVIII-producing sinusoidal endothelial cells could be completely distinguished from lymphatic endothelial cells by expression profiles of podoplanin and CLEC-2; sinusoidal endothelial cells express CLEC-2, whereas lymphatic endothelial cells express its ligand podoplanin. It is very interesting that two molecules acting as receptor-ligand relationship could separate the characteristics between these cells. Podoplanin on lymphatic endothelial cells plays an essential role for the blood/lymphatic separation and lung development through the interaction with CLEC-2 on platelet surface25. Further analysis will be required to identify the ligand for CLEC-2 on sinusoidal endothelial cells because the physiological role of CLEC-2 on sinusoidal endothelial cells still remains unknown.

We did not observe FVIII-producing endothelial cells until E12.5 and found that sinusoidal endothelial cells expressing FVIII surged at E14.5 during embryonic development. These data suggest that the FVIII production system matures in the later phase of liver development. EGFP expression profile in sinusoidal endothelial cells just after birth was similar to those in adult liver. This is consistent with previous clinical observation that plasma FVIII:C in newborn is the same as the adult, whereas levels of vitamin K-dependent coagulation factors at birth are significantly lower than those of adults28. Sinusoidal development follows a series of processes29. First, sinusoidal endothelial cells are lined by a laminin-rich basal membrane, then start to fenestrate by stereotypic differentiation at E14–15, and finally undergo maturation of their anatomical structure29,30. Our investigation of the profile of FVIII-producing cells could help identify the factor(s) responsible for sinusoid maturation because the expression of FVIII seems to occur during the later phase.

VWF and FVIII circulate within the blood as a tight complex in which VWF stabilizes the structure of FVIII and protects it from proteolytic degradation31. It was previously reported that VWF is mainly expressed in capillary endothelial cells but not in lymphatic endothelial cells, whereas FVIII is expressed in lymphatic endothelial cells, suggesting a differential pattern of expression between the proteins20. However, EGFP expression by the F8 gene promoter was not observed in lymphatic endothelial cells in this study. We observed predominant VWF expression in endothelial cells of the central vein; hence, our data also suggest that vascular endothelial cells are the main source of circulating VWF. However, it should be noted that most VWF molecules exist in a nonbinding form with FVIII in the circulation because plasma concentration of VWF is significantly higher than those of FVIII (50 nM and 1 nM, respectively)32. In this study, sinusoidal endothelial cells also expressed VWF at lower levels, and VWF colocalized with EGFP-positive cells in F8Δ knock-in mice. It is conceivable that formation of the FVIII/VWF complex occurs within the cells. Indeed, human endothelial cells stimulated with vasopressin in vitro secreted cell-anchored ultralarge VWF strings covered with bound FVIII19. Further analysis is needed to clarify the involvement of VWF in the endothelial cell secretion of FVIII.

The current adeno-associated virus (AAV) vector-mediated gene therapy for hemophilia expresses the target coagulation factor in hepatocytes33,34,35, which are non-physiological cells for producing FVIII. A recent study revealed that the plasma activity of FVIII ectopically expressed from hepatocytes by AAV-mediated gene therapy was 1.3- to 2.0-fold higher in a one-stage coagulation assay than in a chromogenic substrate assay36. The F8 gene sequence is identical, indicating that FVIII has undergone unique post-transcriptional modifications in hepatocytes. Ectopic post-transcriptional modifications have been suggested to affect the folding, trafficking, and secretion of FVIII in hepatocytes and alter cell viability and function via endoplasmic reticulum stress37. Moreover, FVIII expression in hemophilia A gene therapy tends to gradually decrease over time compared to that in hemophilia B. Hemophilia A gene therapy also required the administration of huge amounts of AAV vectors in clinical trials, even though the molar concentration of FVIII is much lower than that of FIX33. Gene therapy targeting FVIII-producing cells may resolve these problems. Liver sinusoid endothelial cells are almost quiescent under the physiological state38, representing an ideal target for AAV-mediated gene therapy. Therefore, we are currently developing strategies to efficiently introduce AAV vectors into FVIII-producing cells in vivo for hemophilia A gene therapy and genome editing. Furthermore, it has been reported that the administration of sinusoidal endothelial cells expressing FVIII generated from patient-derived induced pluripotent stem cells (iPSCs) improved the hemophilia A phenotype in mice39. Deriving sinusoidal endothelial cells from the patient’s gene-corrected iPSCs may also provide an attractive source for cell-based hemophilia A therapy.

This study has some limitations. First, we must consider the species differences to extrapolate the implications of this study to human biology. It is possible that the mechanism of FVIII synthesis differs among species. Indeed, several reports suggest the existence of a compensatory mechanism by other organs to maintain the plasma FVIII. In a porcine model of fulminant hepatic failure caused by a total hepatectomy, plasma FVIII levels increased in the absence of the liver40. In addition, previous observations in dogs and humans suggest that the liver may not be the unique organ that produces FVIII. In fact, when the liver of a hemophilic dog was transplanted into a normal dog, the recipient did not develop the same phenotype as the hemophilic animal41. In humans, FVIII production was sustained in a transplant recipient of a hemophilia A donor liver42. Second, our study clearly identified FVIII-producing cells in vivo, but we could not assess the cellular localization and release mechanism of FVIII. Because we can only look at EGFP protein instead of FVIII, our data could not consider the protein interaction of FVIII. FVIII localization within the cells might be changed by the interaction with other proteins. Although previous reports suggest that FVIII is packaged with VWF in Weibel–Palade bodies in endothelial cells19, the existence of these bodies in sinusoidal endothelial cells is controversial43.

In conclusion, this study suggested that FVIII in mice is mainly produced from LSECs with expressions of CD31high, CD146high, Lyve1+, and CLEC-2+. Moreover, we found that FVIII production in the liver starts and matures during the later phase of embryonic development. These data help resolve the controversy about which organ-derived endothelial cell types synthesize FVIII. The next challenge will be to elucidate the precise mechanism by which FVIII release is regulated, with the ultimate aim of developing gene therapy to efficiently transduce FVIII-producing cells in vivo.



Wild-type C57BL/6J (WT) mice were purchased from Japan SLC (Shizuoka, Japan). F8fl/fl mice possessing 2 loxP sites flanking exons 17–18 (F8tm1Rmnt/J)13, Alb-Cre mice (B6.Cg-Tg(Alb-Cre)21Mgn/J)44, and lymphatic vascular endothelial hyaluronan receptor-1 (Lyve1)-Cre (B6;129P2-Lyve1tm1.1(EGFP/cre)Cys/J) mice45 were obtained from The Jackson Laboratory (Sacramento, CA, USA). Tie-2-Cre mice (B6.Cg-Tg(Tek-Cre)1Ywa)46 and CAG-Cre mice (B6.Cg-Tg(CAG-Cre)CZ-MO2Osb)47 were obtained from RIKEN BRC (Ibaraki, Japan). The Institutional Animal Care and Concern Committee of Jichi Medical University approved all animal procedures (Approval Number: 17117-13), and animal care was performed according to the committee’s guidelines and as per ARRIVE Guidelines/Checklist.

Generation of F8 knock-in mice

We generated a targeting vector containing a floxed F8 cDNA sequence (exons 16–28), SV40 polyA sequence, and PGK-Neo cassette, followed by linking a 2A-EGFP cDNA and SV40 polyA sequence. Sequences of the 5′ arm (3.0 kb) and 3′ arm (5.6 kb) of F8 were amplified by polymerase chain reaction (PCR) and then inserted into the above construct. The linearized targeting vector was then transduced into mouse embryonic stem cells (ESGRO Complete Adapted C57/BL6 mouse embryonic stem cell Line, Merck, Darmstadt, Germany) by electroporation. To generate chimeric mice, the embryonic stem cells were injected into mouse blastocysts after the confirmation of gene targeting by Southern blotting. Chimeric mice were bred with C57BL/6 mice to produce F1 mice. The F1 mice were bred with CAG-FLPe transgenic mice (F8flox knock-in mice) to delete the PGK-Neo cassette. To generate a systemic deletion of F8 (flox to Δ), F8flox knock-in mice were crossed with CAG-Cre transgenic mice to produce F8Δ knock-in mice. Deletion of F8 cDNA (exons 16–28) was confirmed by PCR analysis using the following primers: F 5′-GTATGTATATGTGTCAGCAAATATGC-3′, R 5′-ATAATTTCACACCATAAGGCCAATA-3′.

Dissociation of cells from primary tissue and flow cytometry

Mice anesthetized with isoflurane were perfused with a perfusion buffer (10 mM HEPES, 140 mM NaCl, 6.5 mM KCl, 5 mM CaCl2, pH 7.4) and their tissues were removed. Bone marrow cells and spleen cells were isolated as previously described48. Other solid tissues were minced into 3–4 mm pieces with scissors and then incubated with 20 µg/mL of Collagenase/Dispase (Roche Applied Science, Mannheim, Germany) and 10 µg/mL of DNase I (Sigma-Aldrich, Louis, MO, USA) for 30 min. Endothelial cells were separated by 25/50% Percoll gradient centrifugation and washed with phosphate-buffered saline (PBS) containing fetal bovine serum.

The expression of EGFP and specific antigens was detected using flow cytometry. Isolated cells were preincubated with an anti-CD16/CD32 mAb to block the Fc receptor (TruStain FcX; BioLegend, Inc., San Diego, CA, USA) and then incubated with fluorescent-conjugated antibodies for 30 min at 4 °C. The following antibodies were used for analyses: anti-CD45.2 mAb conjugated with violetFluor 450 (clone 104; Tonbo Biosciences, San Diego, CA, USA), anti-CD31 mAb conjugated with PE/Cy7 (clone 390), anti-CD146 mAb conjugated with PerCP/Cy5.5 or PE (clone ME-9F1), anti-podoplanin mAb conjugated with PE (clone 8.1.1), anti-CLEC-2 (clone 17D9) conjugated with PE (all BioLegend), and anti-Lyve1 mAb conjugated with eFluor 660 (clone ALY7; Thermo Fisher Scientific, Waltham, MA, USA). Just before analysis, 7-amino-actinomycin D (7-AAD) (BioLegend) or fixable viability dye eFluor 506 (FVD506) (Thermo Fisher Scientific) was added to the samples to detect dead cells. A BD LSRFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) was used to analyze cellular fluorescence, and FlowJo software (BD Biosciences) was used for data analysis.

Immunohistochemical analysis

Mice anesthetized with isoflurane were perfused with 50 mL PBS. For double staining of EGFP with endothelial markers, liver tissues were fixed with 4% paraformaldehyde, incubated with PBS containing sucrose (10–20%), and then frozen in the presence of Tissue-Tek O.C.T. Compound (Sakura Fintek Japan, Tokyo, Japan) in dry ice/ethanol. Tissue sections were blocked with 5% donkey serum and then incubated with an anti-EGFP polyclonal antibody (MBL Co.) and a specific antibody for endothelial markers as follows: anti-CD31 mAb (clone 390; BioLegend), anti-CD146 mAb (clone ME-9F1; BioLegend), anti-CLEC-2 mAb (clone 2A2B10; kindly provided from Dr. Suzuki-Inoue), anti-Lyve1 mAb (clone ALY7; Thermo Fisher Scientific), or anti-VWF polyclonal antibody (code ab11713; Abcam, Cambridge, UK). Sections were then incubated with a species-specific secondary antibody conjugated with Alexa Fluor 594 (Thermo Fisher Scientific) and anti-rabbit IgG conjugated with Alexa Fluor 488 (for the detection of EGFP) for 2 h at 4 °C. Slides were mounted with VECTASHIELD Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Immunofluorescence staining was observed and photographed using a confocal microscope (Leica TCS SP8; Leica Microsystems, Wetzlar, Germany).

Intravital microscopy

Intravital microscopy was performed as reported previously49. Briefly, anesthetized mice were injected with rhodamine B isothiocyanate-Dextran (5 mg/body; Sigma-Aldrich) and Hoechst 33342 (3 mg/body; Thermo Fisher Scientific). A resonance scanning confocal microscope (Nikon A1R; Nikon, Tokyo, Japan) was used to obtain sequential images of the liver.

Isolation of liver endothelial cells of fetal mice

C57BL/6J fetus at E12.5 and E17.5 were sacrificed, and then livers were removed. After treatment of liver tissues with collagenase/dispase and DNase I, the cells were incubated with anti-CD16/CD32 antibody and then stained with fluorescent-labeled antibodies against CD31, CD146, and Lyve1. Dead cells were stained with 7-AAD. A BD FACSAriaII Special Order Research Product (BD Biosciences) was used to isolate the CD31highCD146highLyve1+ cells.

Microarray analysis

The total RNAs were isolated from CD31highCD146highLyve1+ cells in fatal liver (E12.5 and E17.5) by NucleoSpin RNA kit (MACHEREY-NAGEL GmBH & Co, Duren, Germany). mRNA expressions were analyzed by GeneChip Mouse Genome 430 2.0 Array (Thermo Fisher Scientific) and detected by GeneChip Scanner 3000 7G (Thermo Fisher Scientific). Transcriptome Analysis Console software (Thermo Fisher Scientific) was used for data analysis.

Measurement of FVIII activity

FVIII activity (FVIII:C) was measured using an activated partial thromboplastin time (APTT)-based one-stage clotting-time assay on an automated coagulation analyzer (Sysmex CA-500 or CS-1600 analyzer; Sysmex Corp., Kobe, Japan). Clotting time was measured by APTT (Thrombocheck APTT, Sysmex Corp.) after mixing the test mouse plasma with human FVIII-deficient plasma (Thrombocheck FVIII, Sysmex Corp.). FVIII:C was determined based on a calibration curve prepared using pooled plasma from wild-type C57BL/6J mice.

Statistical analyses

Data are presented as means ± standard error of the mean of at least three independent experiments. Statistical significance was determined by 2-tailed Student’s t tests using GraphPad Prism version 8 (GraphPad Software, San Diego, CA, USA) or Microsoft Excel (Microsoft, Redmond, WA, USA). A value of P < 0.05 was considered to be statistically significant.

Data availability

The original data in this study are available upon request from the corresponding author.


  1. 1.

    Thompson, A. R. Structure and function of the factor VIII gene and protein. Semin. Thromb. Hemost. 29, 11–22 (2003).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Hoyer, L. W. Hemophilia A. N. Engl. J. Med. 330, 38–47 (1994).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Bontempo, F. A. et al. Liver transplantation in hemophilia A. Blood 69, 1721–1724 (1987).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Marchioro, T. L., Hougie, C., Ragde, H., Epstein, R. B. & Thomas, E. D. Hemophilia: Role of organ homografts. Science 163, 188–190 (1969).

    ADS  CAS  PubMed  Article  PubMed Central  Google Scholar 

  5. 5.

    Hollestelle, M. J., Geertzen, H. G., Straatsburg, I. H., van Gulik, T. M. & van Mourik, J. A. Factor VIII expression in liver disease. Thromb. Haemost. 91, 267–275 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Do, H., Healey, J. F., Waller, E. K. & Lollar, P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J. Biol. Chem. 274, 19587–19592 (1999).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Groth, C. G. et al. Correction of coagulation in the hemophilic dog by transplantation of lymphatic tissue. Surgery 75, 725–733 (1974).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Veltkamp, J. J. et al. Extrahepatic factor VIII synthesis. Lung transplants in hemophilic dogs. Transplantation 18, 56–62 (1974).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Liu, L., Xia, S. & Seifert, J. Transplantation of spleen cells in patients with hemophilia A. A report of 20 cases. Transpl. Int. 7, 201–206 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Aronovich, A. et al. Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proc. Natl Acad. Sci. U. S. A. 103, 19075–19080 (2006).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Follenzi, A., Raut, S., Merlin, S., Sarkar, R. & Gupta, S. Role of bone marrow transplantation for correcting hemophilia A in mice. Blood 119, 5532–5542 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Everett, L. A., Cleuren, A. C., Khoriaty, R. N. & Ginsburg, D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 123, 3697–3705 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Fahs, S. A., Hille, M. T., Shi, Q., Weiler, H. & Montgomery, R. R. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123, 3706–3713 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Dashty, M. et al. Characterization of coagulation factor synthesis in nine human primary cell types. Sci. Rep. 2, 787 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  15. 15.

    Hollestelle, M. J. et al. Tissue distribution of factor VIII gene expression in vivo—A closer look. Thromb. Haemost. 86, 855–861 (2001).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Jacquemin, M. et al. FVIII production by human lung microvascular endothelial cells. Blood 108, 515–517 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    van den Biggelaar, M. et al. Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells. Haematologica 94, 670–678 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  18. 18.

    Shahani, T. et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J. Thromb. Haemost. 12, 36–42 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. 19.

    Turner, N. A. & Moake, J. L. Factor VIII is synthesized in human endothelial cells, packaged in Weibel–Palade bodies and secreted bound to ULVWF strings. PLoS One 10, e0140740 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  20. 20.

    Pan, J. et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood 128, 104–109 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Breiteneder-Geleff, S. et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154, 385–394 (1999).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Chaipan, C. et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J. Virol. 80, 8951–8960 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Liu, W. et al. Characterization of a novel C-type lectin-like gene, LSECtin: Demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node. J. Biol. Chem. 279, 18748–18758 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  24. 24.

    Pöhlmann, S. et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc. Natl Acad. Sci. U. S. A. 98, 2670–2675 (2001).

    ADS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Suzuki-Inoue, K. et al. Platelet CLEC-2: Roles beyond hemostasis. Semin. Thromb. Hemost. 44, 126–134 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Si-Tayeb, K., Lemaigre, F. P. & Duncan, S. A. Organogenesis and development of the liver. Dev. Cell 18, 175–189 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Nonaka, H., Tanaka, M., Suzuki, K. & Miyajima, A. Development of murine hepatic sinusoidal endothelial cells characterized by the expression of hyaluronan receptors. Dev. Dyn. 236, 2258–2267 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Andrew, M. et al. Development of the human coagulation system in the full-term infant. Blood 70, 165–172 (1987).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  29. 29.

    Ober, E. A. & Lemaigre, F. P. Development of the liver: Insights into organ and tissue morphogenesis. J. Hepatol. 68, 1049–1062 (2018).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  30. 30.

    Enzan, H. et al. Development of hepatic sinusoidal structure with special reference to the Ito cells. Microsc. Res. Tech. 39, 336–349 (1997).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Lenting, P. J., Van Schooten, C. J. & Denis, C. V. Clearance mechanisms of von Willebrand factor and factor VIII. J. Thromb. Haemost. 5, 1353–1360 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Terraube, V., O’Donnell, J. S. & Jenkins, P. V. Factor VIII and von Willebrand factor interaction: Biological, clinical and therapeutic importance. Haemophilia 16, 3–13 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Rangarajan, S. et al. AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530 (2017).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377, 2215–2227 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Ohmori, T., Mizukami, H., Ozawa, K., Sakata, Y. & Nishimura, S. New approaches to gene and cell therapy for hemophilia. J. Thromb. Haemost. 13(Suppl 1), S133–S142 (2015).

    PubMed  Article  Google Scholar 

  36. 36.

    Rosen, S. et al. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. Blood 136, 2524–2534 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Zolotukhin, I. et al. Potential for cellular stress response to hepatic factor VIII expression from AAV vector. Mol. Ther. Methods Clin. Dev. 3, 16063 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  38. 38.

    Poisson, J. et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J. Hepatol. 66, 212–227 (2017).

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Olgasi, C. et al. Patient-specific iPSC-derived endothelial cells provide long-term phenotypic correction of hemophilia A. Stem Cell Rep. 11, 1391–1406 (2018).

    CAS  Article  Google Scholar 

  40. 40.

    Hollestelle, M. J. et al. Extra-hepatic factor VIII expression in porcine fulminant hepatic failure. J. Thromb. Haemost. 3, 2274–2280 (2005).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Webster, W. P. et al. Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am. J. Physiol. 220, 1147–1154 (1971).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  42. 42.

    Madeira, C. L., Layman, M. E., de Vera, R. E., Fontes, P. A. & Ragni, M. V. Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver. Blood 113, 5364–5365 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Lalor, P. F., Lai, W. K., Curbishley, S. M., Shetty, S. & Adams, D. H. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J. Gastroenterol. 12, 5429–5439 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Postic, C. & Magnuson, M. A. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 26, 149–150 (2000).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  45. 45.

    Pham, T. H. et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J. Exp. Med. 207, 17–27 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Kisanuki, Y. Y. et al. Tie2-Cre transgenic mice: A new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230, 230–242 (2001).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  47. 47.

    Matsumura, H., Hasuwa, H., Inoue, N., Ikawa, M. & Okabe, M. Lineage-specific cell disruption in living mice by Cre-mediated expression of diphtheria toxin A chain. Biochem. Biophys. Res. Commun. 321, 275–279 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  48. 48.

    Ohmori, T. et al. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: In vivo model for platelet-targeting gene therapy. FASEB J. 20, 1522–1524 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Nishimura, S. et al. IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J. Cell Biol. 209, 453–466 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


This investigation was supported by grants JP17fk0410306, JP20fk0410017, and JP21fk0410037 (T.O.) from the Japan Agency for Medical Research and Development (AMED), grant 18K08370 (T.O.) from JSPS KAKENHI, SENSHIN Medical Research Foundation (M.H. and T.O.), and The Osaka Foundation for Promotion of Fundamental Medical Research (T.O.). The authors would like to thank Dr. Nobuhiko Kamoshita and Dr. Satoshi Nishimura (Jichi Medical University) for discussions pertaining to the manuscript. The authors would like to thank Yuiko Ogiwara, Yaeko Suto, Mika Kishimoto, Tamaki Aoki, Hiromi Ozaki, Mai Hayashi, Tomoko Noguchi, Nagako Sekiya, and Tomoko Tamura (Jichi Medical University) for their technical assistance. We also thank Enago for editing a draft of this manuscript. BD LSRFortessa (BD Biosciences), a flow cytometer used in this study, was subsidized by JKA through its promotion funds from KEIRIN RACE.

Author information




M.H. and T.O. designed the study, performed experiments, analyzed data, and wrote the manuscript; A.S., H.H., H.M., and N.F. performed experiments and analyzed data; T.H., Y.K., and N.B. helped in data analysis; and Y.S. and K.S.-I. supervised the research and helped in data analysis.

Corresponding authors

Correspondence to Morisada Hayakawa or Tsukasa Ohmori.

Ethics declarations

Competing interests

T.O. received grant support from Novo Nordisk, Mitsubishi-Tanabe, Otsuka Pharmaceutical, Bayer, Dai-ichi Sankyo, and CSL Behring and CHUGAI Pharmaceutical and Japan Blood Products Organization outside of this study. M.H. received a research grant from Bristol-Myers Squibb outside of this study. All other authors declare no competing financial interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hayakawa, M., Sakata, A., Hayakawa, H. et al. Characterization and visualization of murine coagulation factor VIII-producing cells in vivo. Sci Rep 11, 14824 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing